Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: An economic modeling approach

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 1953-1960

  Ananda Rajah, Michelle R ^a,b   Cheng, Allen ^a,c   Morrissey, C Orla ^a,c   Spelman, Tim ^c,d   Dooley, Michael ^c,e   Neville, A Munro ^f   Slavin, Monica ^a,g,h  

^a Infectious Diseases Unit   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

^e Pretium Pty Ltd ^*  (Australia)

^f Pretium   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ECHINOCANDINS; FEMALE; HEMATOLOGY; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, ECONOMIC; MYCOSES; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 79955539945     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01423-10     Document Type: Article

References (36)

1. Baddley, J. W., et al. 2010. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin. Infect. Dis. 50:1559-1567.
2. Bang, H., and A. A. Tsiatis. 2002. Median regression with censored cost data. Biometrics 58:643-649.
3. Barnett, P. G. 2009. An improved set of standards for finding cost for cost-effectiveness analysis. Med. Care 47:S82-S88.
4. Cagnoni, P. J., et al. 2000. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18:2476-2483.
5. Caira, M., et al. 2008. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur. J. Haematol. 81:242-243.
6. Chang, D. C., et al. 2008. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect. Control Hosp. Epidemiol. 29:25-30.
7. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
8. Dasbach, E. J., G. M. Davies, and S. M. Teutsch. 2000. Burden of aspergillosis- related hospitalizations in the United States. Clin. Infect. Dis. 31:1524-1528.
9. De Pauw, B., and J. P. Donnelly. 2007. Prophylaxis and aspergillosis-has the principle been proven? N. Engl. J. Med. 356:409-411.
10. De Pauw, B., et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
11. de With, K., et al. 2005. Hospital use of systemic antifungal drugs. BMC Clin. Pharmacol. 5:1.
12. Dubberke, E. R., K. A. Reske, M. A. Olsen, L. C. McDonald, and V. J. Fraser. 2008. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin. Infect. Dis. 46:497-504.
13. Graves, N., F. Birrell, and M. Whitby. 2005. Effect of pressure ulcers on length of hospital stay. Infect. Control Hosp. Epidemiol. 26:293-297.
14. Graves, N., et al. 2010. Estimating the cost of health care-associated infections: mind your p's and q's. Clin. Infect. Dis. 50:1017-1021.
15. Jegers, M., D. L. Edbrooke, C. L. Hibbert, D. B. Chalfin, and H. Burchardi. 2002. Definitions and methods of cost assessment: an intensivist's guide. ESICM Section on Health Research and Outcome Working Group on Cost Effectiveness. Intensive Care Med. 28:680-685.
16. Kim, A., D. P. Nicolau, and J. L. Kuti. 14 June 2010. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. [Epub ahead of print.]
17. Kontoyiannis, D. P., et al. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50:1091-1100.
18. McLaughlin, A. M., J. Hardt, J. B. Canavan, and M. B. Donnelly. 2009. Determining the economic cost of ICU treatment: a prospective "microcosting" study. Intensive Care Med. 35:2135-2140.
19. Menzin, J., et al. 2005. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health 8:140-148. (Pubitemid 40525375)
20. Menzin, J., et al. 2009. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am. J. Health Syst. Pharm. 66:1711-1717.
21. Morgan, J., et al. 2005. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 26:540-547.
22. Neofytos, D., et al. 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clin. Infect. Dis. 48:265-273.
23. Pagano, L., et al. 2006. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068-1075. (Pubitemid 44208634)
24. Pagano, L., et al. 2010. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95:644-650.
25. Pagano, L., L. Fianchi, and M. Caira. 2008. Pulmonary aspergillosis in hematologic malignancies: lights and shadows. Haematologica 93:1611-1616.
26. Polsky, D., and H. Glick. 2009. Costing and cost analysis in randomized controlled trials: caveat emptor. Pharmacoeconomics 27:179-188.
27. Rentz, A. M., M. T. Halpern, and R. Bowden. 1998. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. 27:781-788.
28. Slavin, M., et al. 2004. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int. J. Infect. Dis. 8:111-120.
29. Slobbe, L., et al. 2008. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin. Infect. Dis. 47:1507-1512.
30. Sorror, M. L., et al. 2005. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919. (Pubitemid 41510773)
31. Tong, K. B., C. J. Lau, K. Murtagh, A. J. Layton, and R. Seifeldin. 2009. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int. J. Infect. Dis. 13:24-36.
32. Ullmann, A. J., et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
33. Van Campenhout, H., S. Marbaix, M. P. Derde, and L. Annemans. 2008. Voriconazole treatment of invasive aspergillosis: real-world versus healtheconomic model results. Clin. Drug Invest. 28:509-521.
34. Wenzel, R., et al. 2005. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J. Antimicrob. Chemother. 55:352-361.
35. Wilson, L. S., et al. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34. (Pubitemid 34160368)
36. Wingard, J. R., et al. 2007. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl. Infect. Dis. 9:182-188.